Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care

On November 6, 2026, Eli Lilly and Company and Hims & Hers Health announced an agreement that gives eligible patients on the Hims & Hers telehealth platform access to Zepbound (tirzepatide; Eli Lilly and Company) and Foundayo (orforglipron; Eli Lilly and Company) at Lilly’s standard self-pay prices. Patients complete a consultation, receive a prescription if a licensed provider deems it appropriate, and have the medication shipped to their home, without leaving the platform. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound.¹

For pharmacists, the deal sharpens a question that has been building since telehealth weight management took off: when the prescription, the fill, and the follow-up all happen inside one digital ecosystem, who sees the full medication list?

Lilly framed the agreement as a way to reach patients where they already seek care, and Hims & Hers noted that its weight loss members receive 24/7 access to a care team, nutrition guidance, and regular clinical check-ins.¹

Hims & Hers also stated that it has never offered compounded copies of Lilly’s GLP-1s and has committed not to do so, and both companies pledged to protect independent clinical decision-making by providers on the platform.¹

Bypassing the Pharmacy Is Not Bypassing the Pharmacist

“I think we need to distinguish between bypassing a traditional community pharmacy and bypassing the pharmacist altogether,” said Aaron Johnson, PharmD, Assistant Professor of Pharmacology and Public Health, Barry University, in email correspondence with Pharmacy Times. “Those are not necessarily the same thing. Even when medications are prescribed and delivered through an integrated telehealth platform, pharmacists remain essential to dispensing, medication safety, and appropriate therapeutic monitoring.”

The larger risk, Johnson said, is fragmentation. A patient filling tirzepatide through Hims & Hers may also be seeing a primary care provider, an endocrinologist, or other specialists, none of whom necessarily has a complete medication history.

That gap matters clinically. Concurrent use with insulin or a sulfonylurea raises the risk of hypoglycemia and may require adjustments to existing therapy, a warning carried in both products’ labeling.¹ Both tirzepatide and orforglipron also carry counseling considerations for patients taking oral hormonal contraceptives; Lilly’s patient safety summaries advise discussing backup contraception for 4 weeks after starting Zepbound and after each dose increase, and for 30 days after starting Foundayo and after each dose increase.¹ For orforglipron specifically, Johnson pointed to clinically relevant interactions with CYP3A4 inhibitors and inducers, as well as specific interactions such as simvastatin.

Beyond interactions, pharmacists should be assessing gastrointestinal tolerability, dehydration, the risk of acute kidney injury, and whether dose escalation is appropriate. “These medications require ongoing clinical oversight, particularly for patients with multiple chronic conditions,” Johnson said.

Johnson does not see telehealth itself as a threat to pharmacy practice but cautioned against models that prioritize convenience without ensuring continuity of care. Pharmacists can stay involved through collaborative medication management, integrated electronic health records, telepharmacy services, medication reconciliation, and direct communication with the patient’s broader health care team.

The question shouldn’t be whether patients physically enter a pharmacy. It should be whether the health care system has preserved the clinical safeguards that pharmacists provide, regardless of where medications are dispensed.—Aaron Johnson, PharmD

A Shifting Compounded GLP-1 Landscape

Wider access to FDA-approved GLP-1 therapies through a large telehealth platform could pull more patients away from compounded alternatives, particularly as the price gap narrows, Johnson said. But a lower advertised self-pay price does not settle the affordability question.

“Foundayo starting at $149 per month and Zepbound at $299 per month may represent meaningful improvements for some patients, but these costs remain prohibitive for others, particularly when obesity treatment requires long-term management,” Johnson said. “This is where I think we need to distinguish between medication availability and meaningful medication accessibility.”

FDA-approved products have undergone standardized evaluation of safety, efficacy, manufacturing quality, and product consistency; compounded drugs do not go through FDA premarket approval. Johnson emphasized that pharmacists should make that distinction clear without implying that all legitimate compounding is unsafe. Compounding has a real place when a patient has individualized needs that commercially available products cannot meet—but compounded GLP-1 products should not be presented as interchangeable with FDA-approved therapies, and their use must comply with federal and state requirements.

In practice, that means counseling on the total cost of treatment rather than the headline monthly price, including:

• Dose-dependent pricing as patients titrate upward
• Insurance coverage and prior authorization status
• Membership or platform fees
• Medication availability
• The financial sustainability of long-term therapy

Pharmacists should also address product quality, the legitimacy of the dispensing pharmacy, and dosing accuracy. “Patients should not have to choose between medication affordability and confidence in the quality of the treatment they receive,” Johnson said. “Affordability remains a public health issue that cannot be solved through distribution models alone.”

Access to Prescriptions vs Long-Term Outcomes

Telehealth can lower real barriers to obesity care—geography, transportation, and the time it takes to get treated—especially for patients with demanding work schedules, caregiving responsibilities, or limited access to specialists. But Johnson drew a line between increasing access to prescriptions and improving long-term health.

Obesity is a chronic, multifactorial disease, and pharmacotherapy is only one component of treatment. Dose titration, adverse effect monitoring, nutritional support, behavioral interventions, and long-term follow-up all remain essential. A platform with regular check-ins and a care team is a promising model, Johnson said, but its value should be judged on measurable outcomes: treatment persistence, weight maintenance, cardiometabolic health, adverse events, and patient-reported experience.

The availability of a once-daily oral option may appeal to patients who want to avoid injections. Still, “oral administration does not eliminate the need for clinical monitoring or individualized treatment decisions,” Johnson said, adding that pharmacists should consider whether patients can realistically sustain a daily regimen over time.

What Pharmacies Should Prepare For

Some GLP-1 dispensing volume is likely to shift toward integrated telehealth and home delivery, and pharmacists will increasingly encounter patients taking these medications from outside their usual network. Johnson said that calls for:

• More comprehensive medication reconciliation that captures therapies obtained through external platforms
• Proactive screening for drug interactions
• Coordinated communication with prescribers, including telehealth clinicians
• Counseling that accounts for medications the pharmacy did not dispense

Pharmacies and health systems should also evaluate how prior authorization requirements, medication availability, and reimbursement structures affect continuity of treatment.

The broader test, Johnson said, is equity. “The most important question is whether these models reduce disparities in obesity care or simply create a more convenient pathway for individuals who already have the financial resources to access treatment,” he said. “Convenience is an important component of accessibility, but it should not be confused with equity.”

REFERENCE

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines. News release. Eli Lilly and Company. November 6, 2026. Accessed November 9, 2026. https://investor.lilly.com/news-releases/news-release-details/lilly-and-hims-hers-expand-access-fda-approved-lilly-medicines